Pacira Pharmaceuticals, Inc. — FY2011 Form 10-K Summary
Business context and reporting period
The filing covers the fiscal year ended December 31, 2011. The source metadata refers to “2011 Q4,” but this is an annual Form 10-K rather than a quarterly filing. Pacira was an emerging specialty pharmaceutical company developing, manufacturing and commercializing DepoFoam-based products for hospitals and ambulatory surgery centers.
EXPAREL, its lead product, was approved by the FDA on October 28, 2011, for single-dose infiltration into the surgical site to provide postsurgical analgesia. EXPAREL had not generated product sales by year-end; the company expected commercial availability and launch in April 2012.
Financial performance and key metrics
| Metric | FY2011 | FY2010 | Change |
|---|---|---|---|
| Total revenue | $15.7 million | $14.6 million | Up 8% |
| Supply and royalty revenue | $10.6 million | $11.3 million | Down 6% |
| Collaborative licensing and development revenue | $5.1 million | $3.2 million | Up 58% |
| Cost of revenues | $16.7 million | $12.3 million | Up 36% |
| Research and development | $14.9 million | $18.6 million | Down 20% |
| Selling, general and administrative | $20.2 million | $6.4 million | Up 217% |
| Loss from operations | $(39.1) million | $(22.7) million | Higher loss |
| Net loss | $(43.3) million | $(27.1) million | Higher loss |
| Net loss per share | $(2.64) | $(47.29) | Per-share comparison affected by 2011 stock issuances and debt conversions |
Approximate margins were a negative gross margin of 6.7%, an operating margin of negative 249%, and a net margin of negative 276%. The filing does not present a positive profitability measure; Pacira reported losses in every year since inception.
- DepoCyt(e) revenue was $10.4 million, while DepoDur revenue was $0.2 million.
- Collaborative revenue included activity under the Novo Nordisk agreement, including a $1.5 million upfront payment and a $2.0 million milestone payment received during 2011; these amounts were deferred and recognized over the estimated contract period.
- A $3.0 million impairment charge consisted of $1.7 million related primarily to DepoDur assets and $1.3 million related to equipment and software made unusable by a change in the EXPAREL manufacturing automation process.
- Stock-based compensation was $2.5 million, compared with $0.02 million in 2010.
Cash flow, liquidity and debt
| Metric | FY2011 | FY2010 |
|---|---|---|
| Cash used in operating activities | $(31.0) million | $(24.9) million |
| Cash used in investing activities | $(36.1) million | $(6.8) million |
| Cash provided by financing activities | $87.2 million | $50.7 million |
| Cash and cash equivalents at year-end | $46.2 million | $26.1 million |
| Short-term investments at year-end | $30.0 million | None reported |
| Working capital | $50.7 million | Not clearly provided in the filing text |
Total cash, cash equivalents and short-term investments were $76.2 million at December 31, 2011. Current assets were $82.6 million and current liabilities were $31.9 million. Restricted cash was $1.3 million in a lockbox supporting the royalty-interest financing arrangement.
Gross principal debt under the Hercules Credit Facility was $26.3 million at year-end, with a blended interest rate of approximately 11.94%. Principal payments were scheduled at approximately $7.0 million in 2012, $9.4 million in 2013 and $9.8 million in 2014. The company was in compliance with its debt covenants at year-end. In addition, the company reported a $2.8 million royalty interest obligation and a $2.0 million contingent purchase liability.
Management stated that existing cash resources and anticipated product revenue were expected to fund operating expenses, capital expenditures and debt service for at least the next 12 months, while also acknowledging that additional financing might be required. The company had no committed external source of additional funds.
Material changes versus prior comparable periods
- Revenue increased 8%, driven primarily by Novo-related collaborative licensing and development activity, while supply and royalty revenue declined 6% as DepoDur sales weakened.
- Operating losses widened substantially as the company built its EXPAREL commercial organization, sales force, manufacturing capacity and public-company infrastructure.
- SG&A increased by $13.8 million, including a $9.8 million increase in selling and marketing expense to $10.2 million.
- R&D declined by $3.8 million as pivotal Phase 3 trials and NDA preparation activities were completed, although EXPAREL pre-commercial manufacturing and compensation costs increased.
- The February 2011 IPO generated approximately $37.1 million of net proceeds, and the November 2011 follow-on offering generated approximately $49.0 million. Existing preferred stock and approximately $51.2 million of notes and accrued amounts converted into common stock upon the IPO.
- Capital spending increased, with $6.2 million used to purchase fixed assets and $30.0 million invested in short-term securities.
- EKR notified Pacira of its intention to terminate the DepoDur licensing, distribution and marketing agreement effective July 1, 2012. Pacira expected future DepoDur supply and royalty revenue to decline and recorded related asset impairments.
Guidance, outlook, commentary and risks
- Management expected EXPAREL to be commercially available and launched in April 2012 after resolving manufacturing challenges that had delayed availability from January 2012.
- The company planned to commercialize EXPAREL initially for postsurgical analgesia by infiltration and pursue a supplemental NDA for nerve-block administration. EXPAREL nerve-block development was in Phase 2, with additional clinical work expected.
- FDA approval included a requirement for pediatric studies over several years and provided three years of U.S. marketing exclusivity through October 28, 2014.
- Management expected continued operating losses and significant sales, marketing, manufacturing, clinical-development and public-company costs. No formal revenue, earnings or launch-sales guidance was provided.
- Key execution risks included timely scale-up and quality-compliant manufacture of EXPAREL, hospital formulary adoption, reimbursement, physician acceptance, competition from generic bupivacaine, opioids, NSAIDs and elastomeric pump systems, and reliance on Quintiles for the outsourced sales force.
- Pacira relied heavily on a limited number of customers: its three largest customers represented 85% of 2011 revenue. Two customers represented 56% and 41% of trade accounts receivable at year-end.
- The company depended on two San Diego manufacturing facilities, third-party raw-material suppliers, cold-chain distribution providers and commercial partners. A manufacturing, supply-chain, regulatory or quality failure could materially impair operations.
- Patent protection for certain EXPAREL composition claims was scheduled to expire in the United States in November 2013, while other patents and pending applications could provide protection into 2017–2023 if enforceable and granted.
- The filing disclosed no material pending litigation. Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2011.
Important facts for investors to verify
- Actual EXPAREL launch timing, initial sales, manufacturing output, gross-to-net deductions and hospital formulary adoption after April 2012.
- Cash burn, debt-amortization requirements and whether additional equity or debt financing was needed after the stated 12-month liquidity window.
- The financial impact of EKR’s July 2012 termination and the resulting decline in DepoDur revenue.
- EXPAREL pricing, reimbursement, market share, competitive response and evidence supporting claimed reductions in opioid use and hospital costs.
- Progress, cost and regulatory status of required pediatric studies and the planned nerve-block indication.
- Whether the company’s manufacturing expansion achieved expected capacity, yields and cost reductions without further impairment or supply interruptions.
- Potential dilution from outstanding options and warrants, and the effect of patent challenges or expirations on EXPAREL’s commercial protection.